HIPO
Hippo Holdings Inc.
HIPO's outlook is improving, though it still trails on the overall score.
MS
Morgan Stanley
MS has the edge over HIPO overall, supported by lower modeled downside and stronger modeled upside.
HIPO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| N/A | |
| N/A |
HIPO's revenue is currently strong, and its profitability is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like HIPO.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
HIPO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.3x | $8.14 | -78% |
| Fair | 7.7x | $9.87 | -73% |
| Expensive | 11x | $14.71 | -60% |
| Forward | 23x | $36.96 | — |
| Current | 29x | $36.96 | — |
Historical ranges are pointers, not guarantees.
HIPO's PE is in its expensive range at 29x. If earnings grow as analysts expect, today's price would be 23x next year's earnings.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS has the edge over HIPO in the historical PE scenario, which offers more potential upside but is not a forecast.
HIPO Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect HIPO to return to profit, with revenue growing.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
HIPO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.58 | +23% |
| Q3 2026 | $1.29 | -65% |
| Q2 2026 | $4.73 | +$5.12 |
| Q1 2026 | $4.40 | +$6.48 |
| Q4 2025 | $2.22 | +$3.86 |
| Q3 2025 | $3.72 | +$8.89 |
| Q2 2025 | -$0.39 | +$6.68 |
| Q1 2025 | -$2.08 | +$7.96 |
| Q4 2024 | -$1.64 | +$9.94 |
HIPO earned $1.29 per share over the past year, down 65% from the year before.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over HIPO on earnings, with more consistent year-over-year improvement.
HIPO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $156M | +29% |
| Q2 2026 | $144.7M | +23% |
| Q1 2026 | $121.5M | +10% |
| Q4 2025 | $120.4M | +18% |
| Q3 2025 | $120.6M | +26% |
| Q2 2025 | $117.3M | +31% |
| Q1 2025 | $110.3M | +30% |
| Q4 2024 | $101.9M | +58% |
HIPO has the edge over MS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.7% | -76 points |
| Q2 2026 | 7.6% | +4.2 points |
| Q1 2026 | 5.9% | +47 points |
| Q4 2025 | 5.7% | -41 points |
| Q3 2025 | 81% | +87 points |
| Q2 2025 | 3.4% | +44 points |
| Q1 2025 | -41% | -2.7 points |
| Q4 2024 | 46% | +107 points |
HIPO's operating margin was 5.7% last quarter, down 76 points from the same quarter a year ago.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS's revenue has grown year over year for 14 quarters in a row: $20.3B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS has the edge over HIPO on profitability, with a higher operating margin.
HIPO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $72.2M | +330% |
| Q2 2026 | $43M | +73% |
| Q1 2026 | $8.4M | +$44.1M |
| Q4 2025 | $3.2M | +$9.7M |
| Q2 2025 | $24.8M | +$35.5M |
| Q1 2025 | -$35.7M | -303% |
| Q4 2024 | -$6.5M | +$42.4M |
| Q2 2024 | -$10.7M | +$27.6M |
HIPO has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
HIPO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +478K shares |
| 1 year | +3.9% | +1M shares |
| 3 years | +14% | +3.3M shares |
| 5 years | +21% | +4.7M shares |
| Available history | +5479% | +26.5M shares |
HIPO has 27M diluted shares, up 3.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q4 2024 | $15.6M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | $1.6M |
| Q1 2023 | $200,000 |
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over HIPO on shareholder dilution, with a more favorable share count trend.
HIPO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2025 | -8.7x | Net Cash |
HIPO has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like HIPO.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
HIPO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.3 | Neutral |
| Stochastic | 68.3 | Neutral |
HIPO's weekly RSI is 63 (neutral) and its Stochastic is 68 (neutral).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
HIPO PE vs Financial Services Sector
| Metric | HIPO | Sector median | Relative |
|---|---|---|---|
| PE | 29x | 13x | 120% above |
| PE % | 100 | 62 | 38 pts above |
HIPO is trading at 29x earnings, a 120% premium to the Financial Services sector's median of 13x.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS has the edge over HIPO on valuation relative to its sector.
HIPO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.9 | 6% above |
| 20 week MA | $32.7 | 13% above |
| 50 week MA | $29.9 | 24% above |
| 100 week MA | $29.4 | 26% above |
| 200 week MA | $22.6 | 63% above |
HIPO has the edge over MS on trend strength, trading above more of its moving averages.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
HIPO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $296.3 | $77.3 | -74% |
| 2022 | $77.3 | $12.1 | -84% |
| 2023 | $12.1 | $9.12 | -25% |
| 2024 | $9.12 | $27.4 | +200% |
| 2025 | $27.4 | $31.3 | +14% |
| 2026 YTD | $31.3 | $37.0 | +18% |
HIPO has the edge over MS on returns for 2026, with the stronger performance.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.